Casgevy: A Year of Transformative Gene Therapy and Expanding Hope
December 2025 Update: From Breakthrough to Real-World Impact It’s been an incredible journey since the U.S. FDA made history by approving Vertex and CRISPR Therapeutics’ gene-editing therapy, Casgevy (exagamglogene autotemcel), for both Sickle Cell Disease (SCD) and Beta Thalassemia. What began as a monumental scientific
